European journal of nuclear medicine and molecular imaging · 2025
[18F]SiTATE PET for PRRT selection and monitoring metastatic tumors of the adrenal medulla and extra-adrenal paraganglia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siegmund Sophie C, Holzgreve Adrien, Schöll Magdalena, Wenter Vera U, Sheikh Gabriel T, Scheifele Maximilian, Gildehaus Franz Josef, Lindner Simon, Auer Matthias K, Lottspeich Christian, Kroiß Matthias, Nölting Svenja, Völter Friederike, Spitzweg Christine, Auernhammer Christoph J, Werner Rudolf A, Zacherl Mathias J
Аннотация
PURPOSE: In somatostatin receptor (SSTR)-expressing tumors, theranostics with SSTR-directed imaging and therapy showed promising results regarding disease control. This study evaluated the use of PET imaging with [18F]SiTATE in pheochromocytoma and paraganglioma (PPGL) patients, focusing on eligibility for peptide radioreceptor therapy (PRRT) and therapy monitoring.
METHODS: Five patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [18F]SiTATE applying the Krenning score and baseline SUVmax. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).
RESULTS: At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUVmax 41.4 ± 87.3) and a high Krenning Score of 3-4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.
CONCLUSION: In metastatic PPGL, [18F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.
METHODS: Five patients with metastatic paraganglioma (n = 3) or pheochromocytoma (n = 2) were included. Eligibility for PRRT was assessed by [18F]SiTATE applying the Krenning score and baseline SUVmax. Treatment response was analyzed by RECIST 1.1 criteria, total tumor volume (PET-based TTV), and Chromogranin A (CgA).
RESULTS: At baseline, all patients showed high lesional uptake, with the highest in the bone (mean SUVmax 41.4 ± 87.3) and a high Krenning Score of 3-4, Suggestive for PRRT eligibility. At the follow up, 2.5 months after completion of PRRT, all patients presented with stable disease (RECIST 1.1) and decreasing or stable CgA levels, whereas TTV increased in three patients and thus showed heterogenous response.
CONCLUSION: In metastatic PPGL, [18F]SiTATE effectively visualizes tumor burden and supports patient selection and response assessment for PRRT. Notably, the data revealed a heterogenous response across PET-based, CT-based, and biochemical assessments. The underlying mechanisms of these discrepancies remain unclear and warrant further investigation.